Evidence map›Paper›PMID 28620205›Full record

ArticleScientific reports2017

An anti vimentin antibody promotes tube formation.

Mathias Lindh Jørgensen, Carina Kjeldahl Møller, Lasse Rasmussen, Louise Boisen, Henrik Pedersen, Peter Kristensen

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Biomarker Potential of Vimentin in Oral Cancers.Life (Basel, Switzerland) · 2022
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mathias Lindh JørgensenDepartment of Engineering, Gustav Wieds Vej 10, Aarhus University, 8000, Aarhus C, Denmark.
Carina Kjeldahl MøllerDepartment of Molecular biology, Gustav Wieds Vej 10, Aarhus University, 8000, Aarhus C, Denmark.
Lasse RasmussenDepartment of Molecular biology, Gustav Wieds Vej 10, Aarhus University, 8000, Aarhus C, Denmark.
Louise BoisenDepartment of Molecular biology, Gustav Wieds Vej 10, Aarhus University, 8000, Aarhus C, Denmark.
Henrik PedersenDepartment of Engineering, Gustav Wieds Vej 10, Aarhus University, 8000, Aarhus C, Denmark.
Peter KristensenDepartment of Engineering, Gustav Wieds Vej 10, Aarhus University, 8000, Aarhus C, Denmark. pk@eng.au.dk.ORCID 0000-0001-7205-6853
Aarhus University · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, there has been an increasing appreciation of the importance of secreted and extracellular proteins that traditionally have been considered as intracellular components. Vimentin is a highly abundant intermediate filament protein, and its intracellular functions have been investigated in a large number of studies. Recently, however, vimentin has been shown to take part in significant processes outside the cell. Our understanding of the functions of extracellular vimentin is, however, limited. In this study we demonstrate that a vimentin specific antibody, obtained by phage antibody technology, promotes tube formation of endothelial cells in a 2D matrigel assay. By binding vimentin, the antibody increases the tube formation by 21% after 5 hours of incubation. Addition of the antibody directly to cultured endothelial cells does not influence endothelial cell migration or proliferation. The enhanced tube formation can be seen for up to 10 hours where after the effect decreases. It is shown that the antibody-binding site is located on the coil 2 domain of vimentin. To our knowledge this is the first study that demonstrates an enhanced tube formation by binding vimentin in a 2D matrigel assay under normoxic conditions.

Indexed as

Angiogenesis InhibitorsAnimalsAntibodies, MonoclonalCell LineCells, CulturedEndothelial CellsHumansMembrane ProteinsMiceNeovascularization, PhysiologicProtein BindingSingle-Chain AntibodiesVimentinAngiogenesis InhibitorsAntibodies, MonoclonalMembrane ProteinsSingle-Chain AntibodiesVimentin

Identifiers

PMID28620205
PMCPMC5472577
OpenAlexW2623909044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.